💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Technetium Tc 99M Arcitumomab

CHEMBL1743090 Phase 4 ได้รับการอนุมัติ Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
98.9 g/mol
LogP
—
Phase
4

Technetium Tc 99m arcitumomab (CEA-Scan) is a radiolabeled anti-CEA (carcinoembryonic antigen) antibody fragment (Fab') used for immunoscintigraphy to detect and localize recurrent or metastatic colorectal cancer. By targeting CEA overexpressed on colorectal cancer cells, it enables scintigraphic identification of tumor deposits not detected by conventional imaging. The use of an antibody fragment rather than whole antibody reduces immunogenicity and improves biodistribution for imaging purposes.

น้ำหนักโมเลกุล

98.9063 g/mol

TPSA

0.00 Ų

กลไกการออกฤทธิ์

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

SMILES

[99Tc]

InChI

InChI=1S/Tc/i1+1

Molecular Formula

Tc

HBD / HBA

- / -

พันธะที่หมุนได้

0

อะตอมหนัก

1

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Technetium Tc 99m arcitumomab (CEA-Scan) is a radiolabeled anti-CEA (carcinoembryonic antigen) antibody fragment (Fab') used for immunoscintigraphy to detect and localize recurrent or metastatic colorectal cancer. By targeting CEA overexpressed on colorectal cancer cells, it enables scintigraphic identification of tumor deposits not detected by conventional imaging. The use of an antibody fragment rather than whole antibody reduces immunogenicity and improves biodistribution for imaging purposes.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Technetium Tc 99M Arcitumomab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743090. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 26476. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.